Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer?

IF 0.2 4区 医学 Q4 PATHOLOGY
O. Vural Topuz , T.S. Akkurt , G.U. Erdem , E.M. Kaya , M. Kaya , B.E. Akkaş
{"title":"Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer?","authors":"O. Vural Topuz ,&nbsp;T.S. Akkurt ,&nbsp;G.U. Erdem ,&nbsp;E.M. Kaya ,&nbsp;M. Kaya ,&nbsp;B.E. Akkaş","doi":"10.1016/j.mednuc.2024.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To assess the utility of metabolic parameters obtained from baseline and post-neoadjuvant chemotherapy (NAC) 18F FDG PET/CT scans in predicting postoperative residual cancer burden (RCB) scores in locally-advanced breast cancer (LABC).</p></div><div><h3>Methods</h3><p>In our retrospective study, we enrolled 58 LABC patients who underwent baseline and post-treatment 18F FDG PET/CT scans followed by surgery between June 2020 and February 2022. Patients were categorized by their molecular subtypes as Luminal groupe (Luminal A and Luminal B (HER 2 negative)), HER2 positive and triple-negative (TN). We recorded various metabolic parameters, including maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake lean body mass (SULmax), and mean SUV lean body mass (SULmean) of the primary tumor (T). To minimize the effect of SUV changes between PET studies, SUV ratios of tumor and liver were recorded for each study as TLR1 and TLR2 respectively. We calculated the percent reduction in SUVmax (ΔSUVmax%) between 2 PET studies. Patients were categorized into two groups based on postoperative RCB scores: RCB0/I (pathological responders, pR) and RCB II/III (pathological non-responders, non-pR).</p></div><div><h3>Results</h3><p>Twenty-six patients (44.8%) were pR and 32 (55.2%) were non-pR. Baseline metabolic parameters were similar in 2 groups. Post-treatment T SUVmax2, T SUVmean2, T SULmax2, T SULmean2, TLR SUV2, and TLR SUL2 values were significantly different between the pR and non-pR patients across all molecular subgroups. Also, pR patients exhibited a significantly higher mean ΔSUVmax compared to non-pR patients. In the Luminal and HER2 positive groups, T SUVmax2 and T SUVmean2 values successfully discriminated the pR and non-pR groups with high accuracy, achieving 100% sensitivity and 100% specificity in the luminal group. In the luminal group, a −75.4% cut-off value for ΔSUVmax predicted pR with 100% sensitivity.</p></div><div><h3>Conclusion</h3><p>Our findings indicate that SUV parameters, normalized to lean body mass as recommended by PERCIST, can be valuable for the early non-invasive prediction of pR and non-pR patients using post-NAC 18F FDG PET/CT.</p></div>","PeriodicalId":49841,"journal":{"name":"Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique","volume":"48 3","pages":"Pages 141-149"},"PeriodicalIF":0.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S092812582400233X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To assess the utility of metabolic parameters obtained from baseline and post-neoadjuvant chemotherapy (NAC) 18F FDG PET/CT scans in predicting postoperative residual cancer burden (RCB) scores in locally-advanced breast cancer (LABC).

Methods

In our retrospective study, we enrolled 58 LABC patients who underwent baseline and post-treatment 18F FDG PET/CT scans followed by surgery between June 2020 and February 2022. Patients were categorized by their molecular subtypes as Luminal groupe (Luminal A and Luminal B (HER 2 negative)), HER2 positive and triple-negative (TN). We recorded various metabolic parameters, including maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake lean body mass (SULmax), and mean SUV lean body mass (SULmean) of the primary tumor (T). To minimize the effect of SUV changes between PET studies, SUV ratios of tumor and liver were recorded for each study as TLR1 and TLR2 respectively. We calculated the percent reduction in SUVmax (ΔSUVmax%) between 2 PET studies. Patients were categorized into two groups based on postoperative RCB scores: RCB0/I (pathological responders, pR) and RCB II/III (pathological non-responders, non-pR).

Results

Twenty-six patients (44.8%) were pR and 32 (55.2%) were non-pR. Baseline metabolic parameters were similar in 2 groups. Post-treatment T SUVmax2, T SUVmean2, T SULmax2, T SULmean2, TLR SUV2, and TLR SUL2 values were significantly different between the pR and non-pR patients across all molecular subgroups. Also, pR patients exhibited a significantly higher mean ΔSUVmax compared to non-pR patients. In the Luminal and HER2 positive groups, T SUVmax2 and T SUVmean2 values successfully discriminated the pR and non-pR groups with high accuracy, achieving 100% sensitivity and 100% specificity in the luminal group. In the luminal group, a −75.4% cut-off value for ΔSUVmax predicted pR with 100% sensitivity.

Conclusion

Our findings indicate that SUV parameters, normalized to lean body mass as recommended by PERCIST, can be valuable for the early non-invasive prediction of pR and non-pR patients using post-NAC 18F FDG PET/CT.

新辅助化疗后 18F-FDG PET/CT 能否预测局部晚期乳腺癌的残余癌肿?
目的 评估从基线和新辅助化疗(NAC)后 18F FDG PET/CT 扫描中获得的代谢参数在预测局部晚期乳腺癌(LABC)术后残留癌负荷(RCB)评分中的实用性。方法 在我们的回顾性研究中,我们纳入了 58 例 LABC 患者,他们在 2020 年 6 月至 2022 年 2 月期间接受了基线和治疗后 18F FDG PET/CT 扫描,随后进行了手术。患者按分子亚型分为Luminal组(Luminal A和Luminal B(HER 2阴性))、HER2阳性和三阴性(TN)。我们记录了各种代谢参数,包括原发肿瘤(T)的最大标准化摄取值(SUVmax)、平均 SUV(SUVmean)、代谢肿瘤体积(MTV)、总病变糖酵解(TLG)、最大标准化摄取瘦体重(SULmax)和平均 SUV 瘦体重(SULmean)。为尽量减少 PET 研究之间 SUV 变化的影响,每次研究中肿瘤和肝脏的 SUV 比值分别记录为 TLR1 和 TLR2。我们计算了两次 PET 研究之间 SUVmax 的降低百分比(ΔSUVmax%)。根据术后 RCB 评分将患者分为两组:结果26例患者(44.8%)为pR,32例(55.2%)为非pR。两组患者的基线代谢参数相似。在所有分子亚组中,治疗后 T SUVmax2、T SUVmean2、T SULmax2、T SULmean2、TLR SUV2 和 TLR SUL2 值在 pR 和非 pR 患者之间存在显著差异。此外,pR 患者的平均 ΔSUVmax 也明显高于非 pR 患者。在管腔组和 HER2 阳性组中,T SUVmax2 和 T SUVmean2 值成功地高精度区分了 pR 和非 pR 组,在管腔组中达到了 100% 的灵敏度和 100% 的特异性。结论我们的研究结果表明,按照 PERCIST 的建议将 SUV 参数归一化到瘦体重,可用于使用 NAC 后 18F FDG PET/CT 对 pR 和非 pR 患者进行早期无创预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
160
审稿时长
19.8 weeks
期刊介绍: Le but de Médecine nucléaire - Imagerie fonctionnelle et métabolique est de fournir une plate-forme d''échange d''informations cliniques et scientifiques pour la communauté francophone de médecine nucléaire, et de constituer une expérience pédagogique de la rédaction médicale en conformité avec les normes internationales.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信